EVALUATION OF EFFECTIVENESS, SAFETY AND ECONOMY OF MEDICINES CTS649

Description

This research group specialises in the evaluation of drug efficacy, safety and cost. In this multidisciplinary group you can find experts in digestive diseases, primary care physicians, clinical pharmacologists and health economists. They belong to the M�laga Biomedical Research Institute (IBIMA), University of Malaga, Andalusian Public Healthcare System and Center for Biomedical Network Research: hepatic and digestive diseases (CIBERehd). It is also a mentoring centre for the IUPHAR (International Union of Basic and Clinical Pharmacology; https://iuphar.org/clinical-division/mentoring-centers/) clinical pharmacology programme.

Research Topics

Study of Drug-Induced Liver Injury (DILI): Epidemiological investigation, risk factors, establishment of causality, patient stratification, genetic factors, identification of biomarkers, effective treatments and clinical trials.
Mechanisms of Drug-Induced Liver Injury: genetic and epigenetic studies, role of extracellular vesicles and microRNAs, metabolomics, microbiota and inmunophenotyping studies.
Etiopathogenesis, clinical course, biomarkers and non-invasive diagnosis in steatotic liver disease associated with metabolic dysfunction (MASLD) and drug-induced steatosis (DIS).
Health economics and rational use of drugs.
Drug safety and efficacy in primary care.

Scientific-Technical Services

Liver safety assessment for drugs: pharmacoepidemiological studies and artificial intelligence in the study of drug-induced liver damage.
Pharmacovigilance: design and evaluation of safety and efficacy in clinical trials.
Advice and evaluation of the role of medications in the onset and evolution of steatotic liver disease associated with metabolic dysfunction (MASLD).
Health Economics consulting.
Study of drug toxicity in in vitro human cellular models.
Immunophenotyping using flow and mass cytometry.